Newson Clinic is a UK menopause service, with in-person locations and video consultations. Its public information includes progesterone among treatment possibilities. That makes it relevant to a question about hormone care, while leaving a separate question unanswered: which exact medicine and route would a clinician propose for a particular patient?
We reviewed the clinic’s consultation, price and service pages on September 29, 2026, alongside current UK product information. This is a UK service assessment. It is not evidence of US prescribing eligibility, cross-border supply, a guaranteed prescription or the availability of a named capsule through the clinic.
In this article
The appointment is verified; an oral formulary is not
Newson’s consultation page describes assessment of symptoms, medical history and treatment options, including approaches other than hormone therapy. The service page discusses progesterone, estradiol and testosterone within its wider care offering. It lists UK locations including Stratford-upon-Avon, London and Hale as well as video appointments.
Those records verify a clinical menopause service. They do not provide a complete oral-progesterone formulary or show what a particular clinician would prescribe. The purpose guide helps keep the reason for a medicine separate from its name. A video option is an appointment format, not evidence that the clinic can treat or send medicine to readers in every country.
UK product information supplies context, not a clinic stock list
The UK product information for Utrogestan 100 mg identifies soft oral capsules containing micronised progesterone. Its stated indication is adjunctive use with estrogen in postmenopausal women with an intact uterus. That is a specific licensed-product context; it does not establish that Newson would select Utrogestan for the reader or that every progesterone use has the same purpose.
The clinic’s treatment description should not be converted into a promise of that product. Alpha Hormones’ review offers a useful cross-country contrast because its US service explicitly lists an approved oral treatment category. Neither country’s general service description replaces the label and professional explanation for an individual prescription.
The UK capsule’s allergy statement needs exact wording
The Utrogestan product record, last updated March 19, 2025, declares soybean lecithin as an excipient with known effect. It contraindicates use in hypersensitivity to the active ingredient, soya, peanut or other listed excipients. That is more precise than saying the capsule is simply natural or assuming that an allergy warning identifies every ingredient in the same way.
This review does not turn that warning into a claim that Newson supplies Utrogestan or that every progesterone product contains identical ingredients. The excipient guide supports asking for the exact formulation and its applicable ingredient record. A UK product’s information should not be silently replaced with a US brand label, even when both use progesterone as the active medicine.
The clinician type changes the published appointment fee
The current service page lists an initial doctor consultation at £295 and a doctor follow-up at £230. It lists an initial nurse or pharmacist consultation at £195 and a follow-up with those professionals at £165. These are appointment prices, not capsule prices or a single recurring membership charge.
The separately linked prices page did not expose a complete fee table in the text available for this review; the figures above come from the service page’s explicit appointment cards. Fountain’s review illustrates a different purchase model based on prepaid treatment periods. Neither model tells the reader what an unconfirmed medicine will cost without further details about the selected arrangement.
A private assessment does not establish a later NHS prescription
The consultation description explains the clinical discussion, but it does not settle every later prescribing and payment arrangement. A private appointment, a pharmacy’s medicine charge and another clinician’s willingness to take on ongoing care are separate matters. This review cannot verify NHS repeat prescribing, a particular pharmacy or reimbursement for an individual reader.
The follow-up guide suggests clarifying who holds responsibility after the initial assessment. Useful questions concern how the proposed treatment will be communicated, who reviews concerns and what happens if another clinician remains involved. The answer should be recorded as an actual agreement, rather than inferred from a general promise of personalized care or from the existence of video follow-ups.
An oral capsule and a different route are not interchangeable labels
The NHS explanation of Utrogestan distinguishes oral capsules used in hormone replacement therapy from vaginal capsules used for fertility treatment. That distinction is useful medicine identification; it is not permission to substitute one route or product for another. The clinic’s general discussion of progesterone does not itself resolve the form intended for a patient.
The UK product record also includes warnings about somnolence and dizziness. The drowsiness questions guide helps frame practical concerns without supplying a schedule or an instruction to alter treatment. A symptom goal, such as better sleep, should remain distinct from an unwanted effect that needs a professional explanation.
A clear proposal would connect the visit with one medicine record
Newson’s clinical service offers a setting in which the purpose of treatment can be discussed. To become a clear oral-progesterone proposal, that conversation needs the actual product and route, the applicable ingredient information, its intended clinical role and the person responsible for reviewing progress or concerns.
The administrative record should be equally clear about the selected appointment type, additional medicine costs and the follow-up arrangement. None of those details is guaranteed by a public reference to progesterone. Newson belongs in a UK consultation comparison with those limits visible, rather than being presented as a confirmed seller of one capsule or a substitute for an individual prescribing assessment.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Newson Clinic: ConsultationsUK clinical assessment service; no exact oral medicine, individual eligibility or later NHS prescribing agreement confirmed · Checked 2026-09-29
- Newson Clinic: Menopause care and appointment pricesUK provider service, locations and clinician-specific initial/follow-up price cards; appointment fees are not medicine prices · Checked 2026-09-29
- Besins Healthcare UK: Utrogestan 100 mg Capsules, SmPCManufacturer UK product information hosted by emc, last updated March 19, 2025; exact oral product indication and soya/peanut contraindication, not Newson availability · Checked 2026-09-29
- Newson Clinic: PricesUK provider price-page access record; full fee table absent from returned text, so numeric appointment fees use the separately cited service-page cards · Checked 2026-09-29
- NHS: About Utrogestan, micronised progesteroneUK public health medicine information, last reviewed January 5, 2023; oral HRT and vaginal fertility forms are distinguished, not interchangeable instructions · Checked 2026-09-29